Comparing FOXO Technologies (NYSE:FOXO) & U.S. Stem Cell (OTCMKTS:USRM)

FOXO Technologies (NYSE:FOXOGet Free Report) and U.S. Stem Cell (OTCMKTS:USRMGet Free Report) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Profitability

This table compares FOXO Technologies and U.S. Stem Cell’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FOXO Technologies -9,032.01% -1,962.97% -291.90%
U.S. Stem Cell N/A N/A N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for FOXO Technologies and U.S. Stem Cell, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FOXO Technologies 0 0 0 0 N/A
U.S. Stem Cell 0 0 0 0 N/A

Earnings and Valuation

This table compares FOXO Technologies and U.S. Stem Cell’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FOXO Technologies $453,000.00 6.10 -$95.25 million N/A N/A
U.S. Stem Cell $80,000.00 0.00 -$2.86 million N/A N/A

U.S. Stem Cell has lower revenue, but higher earnings than FOXO Technologies.

Risk and Volatility

FOXO Technologies has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, U.S. Stem Cell has a beta of -1.19, suggesting that its share price is 219% less volatile than the S&P 500.

Institutional and Insider Ownership

31.6% of FOXO Technologies shares are owned by institutional investors. 16.9% of FOXO Technologies shares are owned by company insiders. Comparatively, 16.7% of U.S. Stem Cell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

About FOXO Technologies

(Get Free Report)

FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report. The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC.

About U.S. Stem Cell

(Get Free Report)

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for FOXO Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FOXO Technologies and related companies with MarketBeat.com's FREE daily email newsletter.